Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dinutuximab with Cytokines and Isotretinoin in High-Risk Neuroblastoma
NCT02169609Phase 2Completed
- Sponsor
- Fundació Sant Joan de Déu
- Start
- Nov 2014
- Primary completion
- Dec 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dinutuximab in neuroblastoma, sponsored by Fundació Sant Joan de Déu. Primary endpoint: Number of Participants with Serious and Non-Serious Adverse Events at 7 months. Started Nov 2014; status: completed.
02
Drugs
dinutuximab
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT02169609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02169609.